Deals News Hubb
Advertisement Banner
  • Home
  • Business Deals
  • Shopping Deals
  • Contact
No Result
View All Result
  • Home
  • Business Deals
  • Shopping Deals
  • Contact
No Result
View All Result
Gourmet News Hubb
No Result
View All Result
Home Business Deals

GSK stops trials of UTI antibiotic early as studies meet main goals

admin by admin
November 3, 2022
in Business Deals


JHVEPhoto/iStock Editorial via Getty Images

GSK (NYSE:GSK) said it was stopping enrolment early in two phase 3 trials of its antibiotic gepotidacin for female adults and adolescents, uncomplicated urinary tract infection (uUTI) as the studies met their main goals.

The decision was made after recommendation from the Independent Data Monitoring Committee (IDMC) and was based on an interim analysis of efficacy and safety data in over 3000 patients across the trials.

The British pharma giant said the studies, dubbed EAGLE-2 and EAGLE-3, met the main efficacy goal of combined clinical and microbiological resolution after treatment at the Test-Of-Cure (TOC) visit for gepotidacin versus nitrofurantoin in patients with a confirmed uUTI and a uropathogen sensitive to nitrofurantoin.

The IDMC review did not find any safety concerns, the company added.

GSK said the EAGLE-2 and 3 trials were now closed for recruitment and the company plans to submit an application to the U.S. Food and Drug Administration in H1 2023 seeking approval of gepotidacin.

The full results will presented in 2023.

Gepotidacin is being developed under a partnership with the U.S. government’s Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS).

The phase 3 program for gepotidacin in adults and adolescents consists of three trials: EAGLE-1, EAGLE-2, and EAGLE-3.

EAGLE-2 (non-inferiority uUTI trial, 204989) was evaluating gepotidacin (1500mg administered orally twice daily for 5 days) against nitrofurantoin (100mg administered orally twice daily for five days). The study duration for participants was ~28 days.

EAGLE-3 (non-inferiority uUTI trial, 212390) was also also comparing gepotidacin to nitrofurantoin, but the duration for participants was ~28 days up until follow-up.

EAGLE-1 is non-inferiority urogenital gonorrhoea trial which is evaluating gepotidacin against ceftriaxone plus azithromycin in approximately 600 patients with uncomplicated GC caused by the bacterium NG.



Source link

Previous Post

Elf on the Shelf Alternatives: Reindeer in Here, Mensch on a Bench and More Seasonal Shenanigans

Next Post

Here’s why this billionaire investor says the Fed is on the right track, but a recession is still likely

Next Post

Here's why this billionaire investor says the Fed is on the right track, but a recession is still likely

Recommended

Another big quarter for Big Oil brings more political backlash (NYSE:XOM)

3 months ago

Asia-Pacific markets higher after Wall Street’s rally overnight

4 months ago

Elon Musk’s Twitter is accused of stiffing a private jet company out of $200,000

2 months ago

LEGO Sets Sale + Exclusive Extra 10% Off = Great Deals on Gifts! {Last Chance}

4 months ago

Here’s why this billionaire investor says the Fed is on the right track, but a recession is still likely

3 months ago

Biz Stone says Tesla CEO Elon Musk should not own Twitter despite Jack Dorsey backing

4 days ago

Deals-(-White-)

© 2022 Deals News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Business Deals
  • Shopping Deals
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Business Deals
  • Shopping Deals
  • Contact

© 2022 Deals News Hubb All rights reserved.